Developing new antibiotics to fight drug-resistant infections
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant Diseases
This study is working on developing new antibiotics that can fight tough infections without causing harmful side effects, like hearing loss or kidney problems, so that patients can have safer and more effective treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10912428 on NIH RePORTER |
What this research studies
This research focuses on creating next-generation aminoglycoside antibiotics that can effectively treat multidrug-resistant infections while minimizing harmful side effects. The approach involves synthesizing and optimizing new compounds to enhance their antibacterial properties and reduce toxicity, particularly ototoxicity and nephrotoxicity. The research will utilize various assays to test the effectiveness of these compounds against resistant bacteria and their safety in animal models. Patients may benefit from improved treatment options for serious infections without the risk of hearing loss or kidney damage.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by multidrug-resistant bacteria, particularly those who have limited treatment options.
Not a fit: Patients with infections that are not caused by multidrug-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective antibiotics for patients suffering from multidrug-resistant infections.
How similar studies have performed: Previous research has shown promise in developing new antibiotics with improved safety profiles, indicating potential for success in this area.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Crich, David — University of Georgia
- Study coordinator: Crich, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.